The next-generation product, CLoNeT™ 2.0, is currently under development. CLoNeT™ R&D pipelines are also active for other infectious indications.
At a time of rampant antibiotic resistance, our products promote the use of appropriate antibiotics, reduce artificial pressures on microbes to develop resistance, and contain the spread of resistant organisms.